Your Source for Venture Capital and Private Equity Financings

DERMALA Announces $6.73M Series A Funding

2020-11-13
SAN DIEGO, CA, DERMALA has closed a $6.73 million Series A financing co-led by Johnson & Johnson Innovation and True Wealth Ventures.
DERMALA, a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, has closed a $6.73 million Series A financing.

The Series A financing was co-led by Johnson & Johnson Innovation - JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital Funds, and Cove Fund also joined the financing round.

DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company's #FOBO (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors